INS and metabolic disease: In the KETO cohort, we observed a beneficial effect of VLCKD-MD up to the sixth month of NI, attributed to the increase in bacterial taxa implicated in promoting intestinal health, glucose homeostasis, and insulin sensitivity and negatively associated with different inflammatory or metabolic diseases, as well as with the impairment of barrier function.